Edition:
India

BiondVax Pharmaceuticals Ltd (BVXV.OQ)

BVXV.OQ on NASDAQ Stock Exchange Capital Market

5.36USD
13 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.36
Open
$5.32
Day's High
$5.37
Day's Low
$5.32
Volume
1,899
Avg. Vol
1,881
52-wk High
$7.69
52-wk Low
$4.61

Latest Key Developments (Source: Significant Developments)

Biondvax Plans Phase 3 Clinical Trial Following Receipt Of Scientific Advice From The European Medicines Agency
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Biondvax Pharmaceuticals Ltd ::BIONDVAX PLANS PHASE 3 CLINICAL TRIAL FOLLOWING RECEIPT OF SCIENTIFIC ADVICE FROM THE EUROPEAN MEDICINES AGENCY (EMA).BIONDVAX PHARMACEUTICALS - M-001​ PHASE 3 TRIAL EXPECTED TO TAKE PLACE IN EASTERN EUROPE & BEGIN PRIOR TO 2018/19 FLU SEASON.BIONDVAX-‍EMA'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ADVICE TO FACILITATE PROCEDURES IN COUNTRIES WHERE PHASE 3 STUDY WILL TAKE PLACE​.  Full Article

Biondvax Pharmaceuticals Ltd Reports Qtrly Loss Per Share of NIS 0.01 ‍​
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Biondvax Pharmaceuticals Ltd ::BIONDVAX PHARMACEUTICALS LTD - QTRLY LOSS PER SHARE NIS 0.01 ‍​.  Full Article

BiondVax and NIH sign clinical trial agreement for phase 2 trial for universal flu vaccine
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Biondvax Pharmaceuticals Ltd :BiondVax and NIH sign clinical trial agreement for a phase 2 trial in the U.S. with BiondVax's universal flu vaccine.BiondVax Pharmaceuticals - ‍NIAID is submitting IND to FDA, participant recruitment anticipated to begin after end of 2017/18 flu season​.  Full Article

No consensus analysis data available.